Refractory Polycythemia vera

Drug	Drug Name	Drug Description
DB08877	Ruxolitinib	A kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment.

Drug	Drug Name	Target	Type
DB08877	Ruxolitinib	Tyrosine-protein kinase JAK1	target
DB08877	Ruxolitinib	Tyrosine-protein kinase JAK2	target
DB08877	Ruxolitinib	Cytochrome P450 3A4	enzyme
DB08877	Ruxolitinib	Cytochrome P450 2C9	enzyme
DB08877	Ruxolitinib	Serum albumin	carrier
DB08877	Ruxolitinib	Tyrosine-protein kinase JAK3	target
DB08877	Ruxolitinib	Non-receptor tyrosine-protein kinase TYK2	target

Drug	Drug Name	Phase	Status	Count